Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 5Phase 3 3Phase NA 1Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 147Breast Neoplasms 116Prostatic Neoplasms 61Multiple Myeloma 57Neoplasms 56Lung Neoplasms 50Neoplasm Metastasis 43Ovarian Neoplasms 36Parkinson Disease 4, Autosomal Dominant Lewy Body 35Colorectal Neoplasms 34Leukemia, Lymphocytic, Chronic, B-Cell 33Carcinoma, Renal Cell 27Recurrence 26Leukemia, Myeloid, Acute 26Urinary Bladder Neoplasms 25Carcinoma, Hepatocellular 24Small Cell Lung Carcinoma 23Myasthenia Gravis 22Triple Negative Breast Neoplasms 21Squamous Cell Carcinoma of Head and Neck 20Lymphoma, Large B-Cell, Diffuse 20Endometrial Neoplasms 20Melanoma 19Lymphoma, Follicular 19Nasopharyngeal Carcinoma 18Fallopian Tube Neoplasms 18Stomach Neoplasms 17Non-Muscle Invasive Bladder Neoplasms 16Brain Neoplasms 16Pancreatic Neoplasms 15

Interventions

Sunitinib 2Midazolam 1Imatinib Mesylate 1IDRX-42 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Gastrointestinal Stromal Tumors × 90 days × Clear all
NCT07218926 2026-05-27

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

GlaxoSmithKline

Phase 3 Recruiting
450 enrolled
GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT05208047 2026-05-22

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Cogent Biosciences, Inc.

Phase 3 Active not recruiting
482 enrolled
GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT07585266 2026-05-13

A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)

GlaxoSmithKline

Phase 3 Not yet recruiting
800 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡